Work

The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study.

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.6_suppl.273

Authors: Todd Michael Bauer, Toni K. Choueiri, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. McDermott, M. Dror Michaelson, Leonard Joseph Appleman, Sanjay Thamake, Rodolfo F. Perini, Eric Kristopher Park, Eric Jonasch

Institutions: Sarah Cannon, Tennessee Oncology, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, South Texas Accelerated Research Therapeutics, Fox Chase Cancer Center, University of Miami, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, University of Pittsburgh Medical Center, Merck & Co., Inc., Rahway, NJ, USA (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3135631159

Cites:

Cited by: 27

Related to: 10